Drug Profile
Research programme: anticancer monoclonal antibodies - Abbott/Raven
Alternative Names: Anticancer monoclonal antibodies research programme - Raven/AbbottLatest Information Update: 01 Feb 2013
Price :
$50
*
At a glance
- Originator Abbott Laboratories; Raven biotechnologies
- Class Monoclonal antibodies
- Mechanism of Action Undefined mechanism
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
Highest Development Phases
- Discontinued Cancer
Most Recent Events
- 17 May 2005 Preclinical trials in Cancer in USA (unspecified route)